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Abstract 
Background: Cardiovascular disease (CVD) describes the pathological conditions of the heart and blood vessels. 
Despite the large number of studies on CVD and its etiology, its key modulators remain largely unknown. To this end, 
we performed a comprehensive proteomic analysis of blood plasma, with the scope to identify disease-associated 
changes after placing them in the context of existing knowledge, and generate a well characterized dataset for fur-
ther use in CVD multi-omics integrative analysis.
Methods: LC–MS/MS was employed to analyze plasma from 32 subjects (19 cases of various CVD phenotypes and 
13 controls) in two steps: discovery (13 cases and 8 controls) and test (6 cases and 5 controls) set analysis. Follow-
ing label-free quantification, the detected proteins were correlated to existing plasma proteomics datasets (plasma 
proteome database; PPD) and functionally annotated (Cytoscape, Ingenuity Pathway Analysis). Differential expression 
was defined based on identification confidence (≥ 2 peptides per protein), statistical significance (Mann–Whitney p 
value ≤ 0.05) and a minimum of twofold change.
Results: Peptides detected in at least 50% of samples per group were considered, resulting in a total of 3796 identi-
fied proteins (838 proteins based on ≥ 2 peptides). Pathway annotation confirmed the functional relevance of the 
findings (representation of complement cascade, fibrin clot formation, platelet degranulation, etc.). Correlation of the 
relative abundance of the proteins identified in the discovery set with their reported concentrations in the PPD was 
significant, confirming the validity of the quantification method. The discovery set analysis revealed 100 differentially 
expressed proteins between cases and controls, 39 of which were verified (≥ twofold change) in the test set. These 
included proteins already studied in the context of CVD (such as apolipoprotein B, alpha-2-macroglobulin), as well as 
novel findings (such as low density lipoprotein receptor related protein 2 [LRP2], protein SZT2) for which a mechanism 
of action is suggested.
Conclusions: This proteomic study provides a comprehensive dataset to be used for integrative and functional stud-
ies in the field. The observed protein changes reflect known CVD-related processes (e.g. lipid uptake, inflammation) 
but also novel hypotheses for further investigation including a potential pleiotropic role of LPR2 but also links of SZT2 
to CVD.
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Background
Cardiovascular disease (CVD) is the leading cause of 
morbidity and mortality worldwide [1]. CVD comprises 
multiple clinical conditions affecting the heart and blood 
vessels which may vary in severity. These include coro-
nary artery disease, peripheral arterial disease, rheumatic 
heart disease, heart failure, ischemic stroke, myocardial 
infarction, cardiomyopathy, and others [1]. Common 
molecular features that have been associated to CVD 
include oxidative stress, inflammation and extracellu-
lar matrix remodeling [2, 3]. However, understanding 
the molecular mechanisms underlining the onset and 
progression of the CVD remains incomplete, hindering 
the development of methods for prevention, early diag-
nosis, prognosis and targeted therapies. Early stages of 
CVD can be, at least in part, reversible, but since they are 
clinically asymptomatic, their diagnosis is challenging. 
Furthermore, the available treatment strategies mainly 
aim to suppress the symptoms (i.e. hypertension, hyper-
cholesterolemia and heart load) and not the etiologies of 
the disease [4, 5]. Thus, a need for deeper understand-
ing of the key molecular mechanisms responsible for the 
observed pathology in CVD clearly still exists.
A consensus that has arisen the last years is that to 
tackle a multifactorial and complex disease, such as 
CVD, a global view of the underlying molecular patho-
physiology is required [6]. Towards this direction, several 
genome-wide association studies (GWASs) have been 
conducted in the recent years that support the existence 
of a genetic impact even in late-onset CVD. Smith et al. 
reviewed statistically robust (with regard to multiple 
testing, p < 5 × 10−8) GWAS on late-onset CVD and rela-
tive traits. The analysis highlighted 92 genetic loci being 
associated with coronary artery disease, carotid artery 
disease, ischemic stroke, aortic aneurysm, peripheral 
vascular disease, atrial fibrillation, valvular disease and 
correlates of vascular and myocardial function. While 
only a few of these variations have an established under-
lying mechanism in the disease, the novel molecular 
players and pathways revealed by these studies provide 
new insights in the pathophysiology of the disease [7]. 
However, the biggest part of heritability of cardiovascu-
lar traits is not yet explained. This could be due to the 
low minor allele frequencies and rare variants that are 
excluded in GWASs, as well as the gene-environment 
and gene–gene (epistatic) interactions that are usually 
not taken into account [8]. Along the same lines, multiple 
studies on gene expression in CVD have been conducted 
with the employment of transcriptomics approaches. 
Chen et al. compared 15 studies that yielded in total 706 
genes differentially expressed between coronary artery 
disease and controls, but only 23 of these genes were 
replicated in 2, maximal 3 different studies [9]. These 
differentially expressed genes included annexin A3, 
fibrinogen alpha chain, guanylate kinase 1, haptoglobin 
and interferon gamma. The low number of reproducible 
results may be due to small study cohorts and genetic 
variability [9].
In parallel to the studies on genetic polymorphisms 
and transcriptome, several studies investigating changes 
at the protein level in tissue, plaques, plasma and urine 
associated with CVD have been conducted (reviewed 
in [10]). Investigation at the proteome level is of special 
value when studying disease associated mechanisms, 
as proteins integrate genomic information with envi-
ronmental impact, thus changes at the protein level are 
expected to reflect the disease phenotype especially 
well. Based on the non- (urine) or minimally invasive 
(plasma) means for their collection, analysis of the urine 
and plasma proteome in association to CVD has gained 
special attention. Urinary protein markers that have 
been suggested in this context include orosomucoid 1 
for chronic heart failure [11]; CD14 in stable coronary 
artery disease [12]; and uromodulin in hypertension [13]. 
Extensive analysis of the urine peptidome, using capillary 
electrophoresis–mass spectrometry (CE–MS), has also 
been described revealing biomarker profiles for coronary 
artery disease [14]; heart failure [15]; stroke [16]; hyper-
tension with left ventricular diastolic dysfunction [17, 
18]; and acute coronary syndromes [19].
Multiple protein changes have been also reported to 
date in plasma. These studies, involving use of both gel-
based and non-gel-based techniques (reviewed in [20]), 
addressed the identification of features associated with 
specific CVD phenotypes, including abdominal aneu-
rism progression [21]; fibrin clot-bound proteins in 
acute myocardial infarction [22]; stable coronary artery 
disease pathophysiology [23]; prognostic biomarkers in 
peripheral arterial occlusive disease [24]; venous throm-
boembolism risk prediction [25]; and extracellular matrix 
remodeling in hypertrophic cardiomyopathy [26]. Signifi-
cant changes in multiple proteins included various forms 
of apoliproteins [23]; thrombospondin 1 [10]; alpha 2 
macroglobulin [10]; transthyretin [24]; complement fac-
tor B [24]; platelet-derived growth factor β [25]; and 
fibronectin [26].
Complementing existing studies and to further improve 
on global understanding of molecular mechanisms of 
CVD, we investigated plasma proteomic changes com-
mon to different clinical etiologies and severity of CVD 
from patients undergoing vascular surgery or organ 
donors, where vascular tissue was available for assess-
ment of CVD. The comparison is made to controls of 
expected high inflammatory profile (donors deceased 
from accidents) without any cardiovascular symptom/
event, and results are analyzed in the context of existing 
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relevant literature (workflow is presented in Fig. 1). Mul-
tiple significant findings include changes previously 
reported at the GWAS and other molecular levels, collec-
tively providing a well characterized and comprehensive 
protein dataset to support further data integration stud-
ies in the field.
Methods
Clinical samples
Blood plasma specimens were collected within the con-
text of a prospective study on CVD (part of the FP7 
project SysVASC: Systems Biology to Identify Molecu-
lar Targets for Vascular Disease Treatment), from con-
trol participants with no cardiovascular background 
(n = 13) and CVD patients (n = 19) in Medical Univer-
sity of Graz, Graz, Austria. All control and over 40% of 
the CVD (n = 8) samples were collected from deceased 
donors. The study was approved by the respective local 
ethics committee (approval number: 26-355 ex 13/14). 
CVD subjects were characterized by established vascular 
disease and had at least one of the following conditions: 
peripheral artery disease; coronary artery disease; arterial 
hypertension; cerebral hemorrhage; or carotid stenosis. 
The characteristics of the participants in this study are 
presented in Table 1.
Sample preparation
Plasma samples were processed with the filter-aided sam-
ple preparation protocol, as previously described by Wis-
niewski et  al. [27]. Specifically, protein concentration of 
plasma was determined by Bradford assay and 200 µg of 
protein per sample was mixed with 0.2  ml of 8  M urea 
in 0.1  M Tris/HCl, pH 8.5 (urea buffer). Reduction was 
performed with 0.1 M dithioerythritol (DTE) for 20 min 
(room temperature—RT) and the samples were loaded 
into 30  kDa Amicon Ultra Centrifugal Filters, Ultracel 
(Merck Millipore). The filters were then centrifuged at 
16,000g for 15 min and washed twice with 0.2 ml of urea 
buffer. The concentrates were then mixed with 0.1 ml of 
50  mM iodoacetamide in urea solution and incubated 
in the dark, at RT for 20  min (alkylation), followed by 
centrifugation for 10 min. Then, the filters were washed 
once with 0.1 ml of urea solution and twice with 0.1 ml of 
50 mM  NH4HCO3, pH 8.5. Finally, samples were digested 
with trypsin (proteomics grade) overnight, in the dark at 
RT (trypsin/protein ratio: 1/100) and the peptides were 
collected by centrifugation of the filter units for 10 min 
at 16,000g in clean tubes. The filters were washed once 
more with 40  µl of 50  mM  NH4HCO3 and eluted pep-
tides were collected in the same tube. The eluates were 
lyophilized and stored at − 20 °C until further processing.
Fig. 1 Summary of the workflow followed in the present study. For increased validity, subjects were divided randomly into discovery and test sets. 
After proteomic analysis of the plasma specimens, pathway annotation was performed for the discovery set proteins and their abundance was 
correlated with the respective plasma concentrations in the plasma proteome database. Differentially expressed proteins were defined with the 
following criteria: case/control ratio ≥ 2 or ≤ 0.5; Mann–Whitney p-value ≤ 0.05; protein identifications based on multiple peptides. The differen-
tially expressed proteins with identical expression trend in both sets were shortlisted and extensive literature mining was performed. The resulting 
validated dataset consists of proteins previously found associated with CVD and novel findings to be further investigated in the context of CVD 
pathophysiology
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LC–MS/MS analysis
Five microgram of protein digest was loaded onto a 
Dionex Ultimate 3000 RSLS nano flow system (Dionex, 
Camberly UK). After loading onto a Dionex 0.1 × 20 mm 
5  μm C18 nano trap column at a flow rate of 5  μl/min 
in 0.1% formic acid and 2% acetonitrile, samples were 
applied onto an Acclaim PepMap C18 nano column 
75  μm × 50  cm (Dionex, Sunnyvale, CA, USA), 2  μm 
100  Å at a flow rate of 0.3  μl/min. The trap and nano 
flow column were maintained at 35 °C. The samples were 
eluted with a gradient of solvent A: 0.1% formic acid and 
2% acetonitrile versus solvent B: 0.1% formic acid and 
80% acetonitrile starting at 1% B for 5 min rising to 5% B 
at 10 min then to 25% B at 360 min and 65% B at 480 min. 
The column was then washed and re-equilibrated prior to 
injection of the next sample. The eluent was ionized using 
a Proxeon nano spray ESI source operating in positive 
ion mode into an Orbitrap Velos FTMS (Thermo Finni-
gan, Bremen, Germany). Ionization voltage was 2.6  kV 
and the capillary temperature was 275  °C. The mass-
spectrometer was operated in MS/MS mode scanning 
from 380 to 1600 amu. The resolution of ions in MS1 was 
60,000 and 7500 for higher-energy collisional dissocia-
tion (HCD) MS2. The top 20 multiply charged ions were 
selected from each scan for MS/MS analysis using HCD 
at 40% collision energy. AGC settings were 1,000,000 for 
full scan in the FTMS and 200,000 for MSn. Dynamic 
exclusion was enabled with a repeat count of 1, exclusion 
duration of 30 s.
MS data processing
Protein identification was performed with Proteome 
Discoverer 1.4 (Thermo Scientific) using the SEQUEST 
search engine [28]. Protein search was performed against 
the SwissProt human protein database [29] (30.05.2016) 
containing 20,197 reviewed entries. The following search 
parameters were applied: (i) precursor mass tolerance: 
10  ppm and fragment mass tolerance: 0.05  Da; (ii) full 
tryptic digestion; (iii) max missed cleavage sites: 2; (iv) 
static modifications: carbamidomethylation of cysteine; 
(v) dynamic modifications: oxidation of methionine; (vi) 
event detector mass precision: 2  ppm; (vii) precursor 
mass: 600–5000  Da; (viii) collision energy: 0–1000  eV; 
(ix) target FDR (strict): 0.01; (x) target FDR (relaxed): 
0.05; (xi) FDR validation based on: q-value. Obtained 
results were further processed by applying the follow-
ing filters: (i) high, medium and low confidence pep-
tides (FDR < 10%); (ii) peptide rank up to 5; (iii) peptide 
grouping was enabled and protein grouping was disa-
bled. The list of peptides was exported and processed 
using a clustering approach that allows combining the 
data sets acquired in the course of multiple MS runs. 
This approach groups features (as defined by calibrated 
retention time and mass) into clusters, followed by the 
sequence assignment. In this way, data are harmonized, 
and consistency in sequence assignment when multi-
ple samples are analyzed in individual experiments is 
achieved. In brief, data were processed in the following 
steps: (1) calibration: to adjust for sample to sample LC 
retention time (rt) shifts, rt was calibrated using LOW-
ESS (locally weighted scatterplot smoothing) non-para-
metric regression method [30]. To identify and calibrate 
respective peptides across the whole study, a peptide list 
from one sample (i.e. sample 27—control) covering the 
full mass and rt range was selected as reference, based on 
which alignment/calibration of rt of all samples was per-
formed. (2) Clustering: peptides, as defined by mass and 
calibrated rt, from all exports from Proteome Discoverer 
were compiled into a single file. This compiled list was 
used as an input file for clustering. Clustering was then 
performed according to the following algorithm: all data 
points (pairs of mass and rt) were placed in a 2-dimen-
sional plane. Clusters (mass window of ± 5  ppm and 
retention time window of ± 5% of the feature’s rt) were 
defined and moved until capturing most data points. The 
center of these clusters (pairs of mass and rt) were com-
piled in a “cluster list”, with each of the clusters assigned 
Table 1 Characteristics of the participants
For gender: M male, F female. Hypertension occurrence corresponds to 
systolic blood pressure ≥ 140/90 mmHg. Obesity is defined by a body mass 
index > 30 kg/m2. For dyslipoproteinemia all the following measurements have 
to occur: total cholesterol ≥ 5.2 mmol/l (≥ 200 mg/dl); low-density lipoprotein 
(LDL) cholesterol ≥ 3.4 mmol/l (≥ 130 mg/dl); high-density lipoproteins (HDL) 
cholesterol ≤ 1.0 mmol/l (≤ 40 mg/dl); and triglycerides ≥ 1.7 mmol/l (≥ 150 mg/
dl)
NA not available data
Variable Control group 
(n = 13)
Case group 
(n = 19)
Demographics
 Gender [n (%)] 12 (92.3%) M,  
1 (7.7%) F
10 (52.6%) M, 
9 (47.4%) F
 Age (years) 42.50 ± 16.8 65.8 ± 10.4
Physical characteristics
 Weight (kg) 82.5 ± 8.7 75.1 ± 10.6
 Height (cm) 177.8 ± 9.0 169.3 ± 7.3
 Body mass index (kg/m2) 26.1 ± 2.1 26.2 ± 3.3
Clinical information [n (%)]
 Hypertension 2 (15.4%) 18 (94.7%)
 Obesity 1 (7.7%) 2 (10.5%)
 Diabetes 0 (0%) 5 (26.3%)
 Dyslipoproteinemia 0 (0%), 1 (7.7%) NA 2 (10.5%)
 Left ventricular hypertrophy 1 (7.7%) 6 (31.6%)
 Angina pectoris 0 (0%) 1 (5.3%)
 Intermittent claudication 0 (0%), 1 (7.7%) NA 7 (36.8%)
 Myocardial infarction 0 (0%) 3 (15.8%)
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with a unique identifier. Only clusters with at least 2 
members were considered for further analysis. (3) Match-
ing and sequence assignment: as described above, at this 
stage each cluster includes a set of features (peptides) 
within a certain “window” of mass and rt. For each clus-
ter, the sequence with the highest frequency across the 
study was selected as representative. In case of a tie, the 
sequence with the highest Xcorr was selected. (4) Protein 
annotation: for each assigned sequence, Uniprot ID was 
annotated with protein name and gene symbol, based 
on the respective Uniprot database. In the case of one 
peptide being assigned to multiple proteins, the protein 
represented with highest frequency across the cluster list 
was selected. (5) Retrieve peptide information for further 
quantification: peptide area, confidence, Xcorr and mass/
retention time information were retrieved from the pep-
tide lists of each sample according to their cluster IDs. 
Only peptides < 5  ppm difference between experimental 
and theoretical mass were considered. (6) Quantification: 
Samples were randomly divided into discovery and vali-
dation set based on the rule 2/3 (n = 22, 13 cases and 8 
controls) and 1/3 (n = 11, 6 cases and 5 controls), respec-
tively. Each set of samples was analyzed separately as 
follows: for a limited number of sequences for which no 
peptide area could be retrieved by proteome discoverer 
(this is a well-known, but not yet corrected problem of 
this software), the missing values were replaced by the 
mean area values of that group. When the peptide was 
not identified in the particular sample, the missing values 
were replaced with zero. For the discovery set, only pep-
tides reported in more than 50% of the samples of at least 
one group were included in the differential expression 
analysis, while no filters were applied in the test set anal-
ysis. Subsequently, part per million (ppm)-normalization 
of the peptide peak areas was conducted according to 
the following formula: normalized peak area = (peptide 
peak area/total peak area) × 106. Protein abundance in 
each sample was calculated as the sum of all normalized 
peptide areas for a given protein, as described previously 
[31]. Statistical analysis was based on the Mann–Whit-
ney test performed using R package. Proteins with 
p-value ≤ 0.05 were considered as statistically significant.
Functional analysis
Functional analysis was performed with the ClueGO 
plug-in [32] in Cytoscape 3.4.0 [33] as well as the Inge-
nuity Pathway Analysis software (QIAGEN Inc.) [34]. In 
regard to the ClueGO analysis, ontologies were retrieved 
from REACTOME pathways database (updated on Sep-
tember 4, 2017) and only statistical significant pathways 
(Bonferroni corrected p-value ≤ 0.05, two-sided hyper-
geometric test) were taken into account. For the remain-
ing parameters, default settings were used. Results were 
simplified based on biological relevance and only the 
leading term from each group is presented.
Correlation analysis
Spearman rank correlation analysis was performed using 
IBM SPSS Statistics for Windows, Version 22.0 after log-
arithmic transformation of the values.
Results
Discovery set analysis: establishing validity of the 
proteomics dataset
In total, 32 plasma samples, 13 controls and 19 CVD 
cases, were analyzed by high-resolution LC–MS/MS. To 
establish confidence in the validity of the results from the 
differential expression analysis, the samples were ran-
domly divided into discovery (2/3 of the samples; cor-
responding to 21 samples—13 cases and 8 controls) and 
test (1/3 of the samples; corresponding to 11 samples—6 
cases and 5 controls) sets. In the discovery set, only pep-
tides detected in at least 50% of samples per group (cases 
or controls) were considered, resulting in a total of 3796 
identified proteins. Of these, 838 protein identifications 
were based on at least 2 peptides. The full list of identi-
fied peptides and proteins is provided in Additional file 1. 
To confirm the biological relevance of this dataset, path-
way annotation was performed using the ClueGO plug-in 
of Cytoscape platform (Additional file 2). As shown, the 
detected proteins segregated into (plasma) biologically 
relevant pathways such as complement cascade, scaveng-
ing heme from plasma, fibrin clot formation and platelet 
degranulation (these being among the statistically sig-
nificant formed pathways—Additional file 2). When only 
identifications based on at least 2 peptides were included 
in the analysis, HDL assembly and TGF-b signaling also 
emerged among the statistically significant pathways 
(Additional file  2). Collectively, this phenotyping of the 
findings via pathway annotation verified that the proteins 
identified via the applied proteomics approach are bio-
logically relevant and the ones expected to be found in 
plasma based on the current knowledge.
To assess the reliability of the applied quantification 
approach, the relative abundance of proteins from the 
discovery set was compared to the respective absolute 
concentrations reported in the plasma proteome data-
base (PPD) (http://plasmaproteomedatabase.org/index.
html) [35]. For this comparison, PPD entries originat-
ing from spectral counting experiments on plasma were 
considered. This corresponded to 299 proteins (286 pro-
teins in the controls, 288 proteins in the cases) reported 
in both PPD and our study (listed in Additional file  3). 
Spearman rank correlation analysis revealed significant 
correlation between the reported PPD concentrations 
and the observed protein abundances in our datasets 
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 (rs = 0.521, p-value < 0.0001 for controls; and  rs = 0.536, 
p-value < 0.0001 for cases). Scatter plots of these compar-
isons are presented in Fig. 2. This result supports that the 
applied quantification strategy is appropriate incorporat-
ing state of the art knowledge.
Test set analysis: differential expression analysis reveals 
expected and novel protein changes
To increase reliability in the differential expression anal-
ysis in the discovery set, given also the relatively small 
sample size, only proteins identified based on at least 2 
peptides were considered, and differential expression 
was defined based on statistical significance (Mann–
Whitney p-value ≤ 0.05) and change by at least twofold 
in the cases versus controls. A total of 100 proteins were 
found to meet these criteria (listed in Additional file 1). 
These findings were subsequently examined for valid-
ity in an independent test set of 11 samples, including 5 
controls and 6 cases (the full list of peptides and proteins 
identified in the test set is provided in Additional file 3). 
Spearman rank correlation analysis revealed significant 
correlation between the protein abundances of discovery 
and test sets  (rs = 0.850, p-value < 0.0001 for controls; and 
 rs = 0.893, p-value < 0.0001 for cases). Out of the 100 dif-
ferentially expressed proteins, 39 proteins were detected 
at the same expression trend (up- or down-regulated) 
and with a fold change of at least 2, when comparing 
cases and controls in the test set (Table  2, Additional 
file  3). Of these 39 proteins, 9 showed statistically sig-
nificant changes (Mann–Whitney p-value ≤ 0.05) also in 
the test set (Table 2, Additional file 3) and thirteen were 
described in the past as associated with cardiovascular 
disease, further supporting the validity of our approach. 
As shown in Table 2, the latter proteins included alpha-
2-macroglobulin; apolipoprotein B; heparin cofactor 2; 
lipopolysaccharide-binding protein; latent-transforming 
growth factor beta-binding protein 2; and others.
Interestingly, molecular pathways that these 39 proteins 
participate in, based on the Ingenuity Pathway Analysis 
(IPA), included acute phase signaling; LXR/RXR activa-
tion; interleukin-6 signaling; coagulation system; and 
iNOS signaling (Additional file  4; canonical pathways), 
suggesting potential impact on these processes based on 
the observed protein abundance changes in CVD. In fact, 
and despite the small input dataset (39 proteins), most 
of the aforementioned pathways (with the exception of 
iNOS signaling) were predicted to be changing at statisti-
cally significant levels in the CVD cases versus controls 
(Additional file 4).
Along the same lines, IPA predicted significant enrich-
ment of various cardiovascular system- and lipid metab-
olism-related processes based on the 39 verified proteins; 
these included uptake of lipid; activation of vascular 
endothelial cells; atherogenesis; hypercholesterolemia; 
vasculogenesis; dilated cardiomyopathy; all emerging as 
statistically significant functions reflected in the verified 
proteins (Additional file 4; biological functions).
Discussion
The proteomic findings presented in this study provide a 
good source of information for further analysis and sys-
tems biology approaches. Proteomic data were generated 
from well characterized clinical specimens following a 
high resolution proteomic approach. The latter has been 
extensively optimized to provide a comprehensive view of 
the proteome, without performing abundant plasma pro-
tein depletion, frequently associated with technical vari-
ability and loss of information (from non-specific protein 
removal due to antibody cross-reactivity or protein 
binding) [36]. The identified proteins were investigated 
Fig. 2 Scatter plots showing the relative abundances of identified proteins and their plasma concentration in PPD. a Proteins identified in controls 
and b proteins identified in cases. Scatter plots were created after logarithmic transformation of the values
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Table 2 Shortlisted differentially expressed proteins following the same expression trend in both discovery and test sets
Uniprot ID Name Discovery set Test set CVD relevant 
publications
Number 
of peptides
Cases/
controls
Mann–Whit-
ney p-value
Number 
of peptides
Cases/
controls
Mann–Whitney 
p-value
Q96M60 Protein FAM227B 2 0.44 7.58E−04 2 0.38 8.11E−03
Q03164 Histone-lysine N-methyl-
transferase 2A
2 0.38 9.84E−04 2 0.12 8.11E−03
Q9NVW2 E3 ubiquitin-protein ligase 
RLIM
3 2.66 4.23E−03 4 2.46 8.11E−03
O60494 Cubilin 2 15.19 1.18E−03 2 27.19 1.29E−02
P01023 Alpha-2-macroglobulin 64 2.37 1.27E−03 82 2.50 1.37E−02 [39, 40]
Q02880 DNA topoisomerase 2-beta 3 3.86 2.98E−03 9 3.25 1.37E−02
Q8WWI1 LIM domain only protein 7 2 3.26 4.23E−03 2 3.33 2.25E−02 [76]
O75665 Oral-facial-digital syndrome 
1 protein
2 3.01 1.86E−02 2 3.36 2.25E−02 [77]
P36957 Dihydrolipoyllysine-residue 
succinyltransferase com-
ponent of 2-oxoglutarate 
dehydrogenase complex, 
mitochondrial
2 2.67 4.61E−02 2 5.50 3.53E−02 [78]
O75445 Usherin 2 2.50 3.35E−03 5 9.25 5.52E−02
P05546 Heparin cofactor 2 8 2.99 3.36E−03 17 3.99 5.52E−02 [37, 79]
Q8IZU0 Protein FAM9B 2 2.36 3.36E−03 2 4.14 5.52E−02
A0AUZ9 KAT8 regulatory NSL com-
plex subunit 1-like protein
2 3.30 1.53E−02 2 2.11 5.52E−02
Q92766 Ras-responsive element-
binding protein 1
2 2.31 3.88E−02 2 3.35 6.73E−02
Q5TEZ5 Uncharacterized protein 
C6orf163
4 2.13 1.25E−02 4 2.28 8.28E−02
P54317 Pancreatic lipase-related 
protein 2
2 0.01 4.51E−03 3 Only in 
con-
trols
9.96E−02
Q9H6S0 Probable ATP-dependent 
RNA helicase YTHDC2
3 5.23 4.60E−03 6 2.31 1.21E−01
P01266 Thyroglobulin 3 0.33 9.90E−03 4 0.46 1.21E−01
P08185 Corticosteroid-binding 
globulin
2 2.65 3.26E−02 4 3.35 1.21E−01 [80]
Q5T200 Zinc finger CCCH domain-
containing protein 13
3 8.07 4.18E−03 3 5.71 1.35E−01
P18428 Lipopolysaccharide-binding 
protein
5 0.29 7.55E−04 8 0.43 1.71E−01 [81]
P98164 Low-density lipoprotein 
receptor-related protein 2
5 4.00 1.25E−02 10 3.92 1.71E−01 [58]  
Q5T011 Protein SZT2 2 0.33 1.86E−02 3 0.37 1.71E−01
P04114 Apolipoprotein B-100 68 2.47 3.26E−02 135 2.16 1.71E−01 [41, 42, 46]
Q9NS86 LanC-like protein 2 3 2.54 4.64E−02 3 2.76 1.71E−01
Q9H7L9 Sin3 histone deacetylase 
corepressor complex 
component SDS3
2 4.70 1.84E−02 4 2.50 2.00E−01
O60884 DnaJ homolog subfamily A 
member 2
2 6.36 2.67E−03 2 2.21 2.31E−01
Q5T481 RNA-binding protein 20 4 4.84 9.84E−04 4 4.61 2.35E−01 [47, 82]  
Q5VZL5 Zinc finger MYM-type 
protein 4
2 0.36 5.30E−03 2 0.38 2.62E−01
O15553 Pyrin 2 11.75 1.72E−03 2 2.65 2.74E−01 [49–51, 83]
Q96PV0 Ras/Rap GTPase-activating 
protein SynGAP
2 0.15 7.33E−03 3 0.49 3.11E−01
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regarding their biological relevance, by pathway annota-
tion, and, regarding the reliability of the quantification 
approach, by cross-correlation with the respective PPD 
absolute concentrations. As expected, biological path-
ways, such as acute phase response, interleukin-6, iNOS, 
and atherosclerosis signaling, and functions, such as acti-
vation of vascular endothelial cells, atherogenesis, hyper-
cholesterolemia and transport of lipid, were predicted to 
be deregulated in CVD based on the observed protein 
changes.
To our knowledge, this is the first untargeted proteomic 
study on patients with various CVD-related conditions 
and severities. Thus, this study is expected to represent 
a valid foundation and initiation point for further investi-
gation of common molecular mechanisms that underline 
the variety of CVD traits and conditions.
Interestingly, 13 out of the 39 verified proteins found 
in our analysis have been already associated with CVD 
in the literature (Table 2). As examples, Li et al. recently 
reported that plasma levels of alpha-2-macroglobulin 
positively correlated with higher vulnerability of carotid 
plaques, and increased risk of stroke [37]. In a proteomic 
study of plasma micro-particles, alpha-2-macroglobulin 
was also found upregulated in patients after deep venous 
thrombosis in comparison to healthy subjects [38]. In 
addition, higher alpha-2-macroglobulin serum levels 
were indicators of cardiac complications in HIV patients 
[39] and myocardial infarction in diabetic patients [40].
Along the same lines, apolipoprotein B, which we 
found upregulated in CVD, is widely considered as a 
major causal agent of atherosclerosis, is a structural 
component of plasma lipoproteins [i.e. chylomicron 
remnants, very low-density lipoprotein (VLDL), inter-
mediate-density lipoprotein, LDL, and lipoprotein(a)] 
and mediates cholesterol transport and removal in vas-
cular wall [41]. Apoliprotein B-100, the form identified in 
our study, plays a key role in the binding of LDL particles 
(prominent driver of atherogenesis) to the LDL receptor, 
allowing cells to internalize LDL and thus to absorb cho-
lesterol [42]. Plasma levels of apoliprotein B and ratio of 
apoliprotein B/apoliporotein A–I (controls: 0.21, cases: 
0.29) are increased in CVD compared to controls in our 
analysis. This finding is in agreement with studies corre-
lating increased plasma apolipoprotein B and apolipro-
tein B/apoliporotein A–I ratio with myocardial infarction 
[43–45] and ischemic stroke [46].
In addition, mutations and polymorphisms in genes 
that code for some of the validated differentially 
expressed proteins detected in the present analysis have 
been connected with CVD. This suggests that these 
proteins may play important roles in the pathogenesis 
of CVD, and/or might also serve as early disease mark-
ers, hence are worth further investigation. Examples 
include: Rbm20 (encoding for RNA-binding protein 20) 
whose mutations in exon 9 of the gene have been linked 
to familial dilated cardiomyopathy and associated with 
young age at diagnosis, end-stage heart failure, and high 
mortality [47, 48]; and MEFV (pyrin encoding gene) 
whose mutations are a risk factor for early coronary 
artery disease [49] and are associated with childhood 
Table 2 continued
Uniprot ID Name Discovery set Test set CVD relevant 
publications
Number 
of peptides
Cases/
controls
Mann–Whit-
ney p-value
Number 
of peptides
Cases/
controls
Mann–Whitney 
p-value
Q8N436 Inactive carboxypeptidase-
like protein X2
2 0.46 1.84E−02 3 0.37 3.11E−01
Q14767 Latent-transforming growth 
factor beta-binding 
protein 2
4 0.28 7.58E−04 6 0.43 3.15E−01 [84]
Q8IWB6 Inactive serine/threonine–
protein kinase TEX14
2 4.64 3.84E−02 4 2.43 3.60E−01
Q5T9S5 Coiled-coil domain-con-
taining protein 18
2 0.37 2.01E−02 3 0.25 3.89E−01
Q8N163 Cell cycle and apoptosis 
regulator protein 2
2 0.21 3.51E−02 3 0.17 3.89E−01
Q9GZU1 Mucolipin-1 2 0.35 1.46E−02 3 0.48 4.10E−01
O43301 Heat shock 70 kDa protein 
12A
2 3.16 1.68E−02 2 3.91 4.11E−01 [85]
A6NES4 Maestro heat-like repeat-
containing protein family 
member 2A
2 0.28 7.55E−04 3 0.24 6.48E−01
Mann–Whitney p-values in italics font indicate values ≤ 0.05
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polyarteritis nodosa [50] and vascular complications in 
Behçet’s disease [51].
Within the verified proteins of our study and with no 
previous report in CVD to the best of our knowledge, 
low-density lipoprotein receptor-related protein 2 (LRP2) 
was also detected at increased levels in the plasma of 
CVD subjects in comparison to controls. With LRP2 
interacting with both apolipoprotein B-100, mediating 
endocytosis of low density lipoproteins [52], and cubilin, 
(also upregulated in CVD plasma compared to controls), 
facilitating endocytosis of high density lipoproteins [53], 
we may hypothesize a central role of this protein in the 
accumulation of lipoproteins and the abnormal choles-
terol metabolism occurring during CVD [54].
The central role of LRP2 in CVD is further supported 
via its function as an auxiliary receptor that controls 
sonic hedgehog (Shh) signaling [55]. Both knock-out 
mice for Shh [56] and mice carrying mutations in Lrp2 
[57] exhibit cardiac outflow tract septation defects. 
Moreover, Baardman et al. showed that Lrp2 knock-out 
mice carry a variety of severe cardiovascular abnormali-
ties, such as aortic arch anomalies, ventricular septal 
defects, overriding of the tricuspid valve and marked 
thinning of the ventricular myocardium [58]. Collec-
tively, and considering the observed cardioprotective and 
angiogenic effects of Shh signaling in adulthood [59–61], 
further investigation of LRP2 as a potential central and 
pleiotropic node in CVD is suggested.
One additional finding with no previous association 
to CVD, is Ras-responsive element-binding protein 1 
(RREB1), found at increased levels in the plasma of CVD 
patients compared to controls. Interestingly, RREB1 
is an upstream regulator of the renin-angiotensin sys-
tem acting as a transcriptional suppressor of the angio-
tensinogen gene [62, 63]. Since angiotensinogen is the 
precursor molecule of angiotensins I and II that induce 
vasoconstriction and blood pressure increase [64, 65], we 
may hypothesize that RREB1 may reflect the upregula-
tion of a compensatory mechanism targeting to reduce 
hypertension.
Protein SZT2, that was found downregulated in CVD 
patients’ plasma, has been mainly associated with epi-
leptogenesis and human brain development [66]. Recent 
reports support that SZT2 deficiency leads to increased 
mechanistic target of rapamycin complex 1 (mTORC1) 
signaling [67, 68]. Additionally, hypertrophic signals 
(such as pressure overload, β-adrenergic stimulation 
and angiotensin II) can also induce mTORC1 signaling 
in the heart, resulting in significant phenotypic impact: 
mTORC1 can induce cardiac hypertrophy as a compen-
satory mechanism to maintain function during pressure 
overload but also, and depending on the molecular back-
ground, can induce pathological cardiac hypertrophy 
[69]. Therefore, collectively, we may propose that the 
observed SZT2 decrease in CVD may be linked to 
increased mTORC1 signaling, a hypothesis meriting fur-
ther investigation.
Another protein with no previous association to 
CVD included in the verified list, is lanC-like protein 
2 (LANCL2) found to be at increased plasma levels in 
CVD patients. LANCL2 is the molecular target of absci-
sic acid, a natural phytohormone and an endogenous 
hormone with immune modulatory function [70]. Mag-
none et al. reported that abscisic acid participates in the 
development of atherosclerosis through the activation of 
monocytes and vascular smooth muscle cell responses, 
and its levels in atherosclerotic plaques are significantly 
higher than in normal vessels [71]. On the other hand, 
Guri et  al. showed that feeding apolipoprotein E-defi-
cient (ApoE−/−) mice with abscisic acid can ameliorate 
atherosclerosis by suppressing immune cell recruitment 
into the aortic root wall and upregulating aortic endothe-
lial nitric oxide synthase expression [72]. They also sug-
gested that, considering the findings of the former study 
by Magnone et al. [71], abscisic acid may be a part of a 
lesion-reducing mechanism [72]. Whatever the role of 
abscisic acid in the atherosclerotic plaque is, its func-
tion in inflammation (and presumably atherosclero-
sis) is mediated by LANCL2 [73]. The increased plasma 
LANCL2 levels of CVD patients found in our study, in 
combination with the observed increase of abscisic acid 
in plaques [71], further supports the proposed scheme.
Further proteins identified in this study and of special 
interest for further evaluation may be those that take part 
in cardiovascular system-related processes based mainly 
on animal model studies, but have not been studied in the 
human disease yet. DNA topoisomerase 2-beta (TOP2B) 
is such an example. In the study by Zhang et al. cardio-
myocyte-specific deletion of Top2b protected mice from 
the development of progressive heart failure induced by 
doxorubicin [74]. Doxorubicin inhibits TOP2B, generat-
ing DNA double-strand breaks that are cytotoxic, induce 
pro-apoptotic DNA damage response and can eventually 
lead to cardiomyocyte cell death [74, 75]. Nevertheless, a 
functional connection of the observed increase in plasma 
TOP2B of CVD patients and the disease remains elusive.
Even though informative, our study also has limita-
tions: the sample size is small especially considering the 
disease complexity, corresponding to a low statistical 
power. This largely stems from the fact that these sam-
ples were collected in the context of a prospective study 
where collection of tissue was also targeted to confirm 
disease pathology. To decrease, as possible, potential arti-
facts as a result of impact from this limitation, we applied 
stringent criteria for differential expression and tar-
geted to verify findings based on dataset cross-checking 
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(discovery versus test set; test set versus literature). In 
addition, one further shortcoming is that there is a sig-
nificant mean age difference between cases and controls 
(65.8 versus 43.7 respectively). Nevertheless, following a 
closer data investigation (study expression levels of the 
specific proteins after omitting outliers per group and 
significance in the age difference; data not shown), the 
highlighted changes were not found to be age-associated.
Conclusions
The proteomic analysis performed in this study, compar-
ing plasma samples from CVD patients to control sub-
jects, provides a comprehensive dataset to be used for 
further integrative studies in the future. The observed 
protein changes reflect known CVD-related processes 
such as changes in lipid uptake and inflammatory pro-
cesses. Several novel findings are also highlighted 
forming the basis for hypotheses meriting further inves-
tigation including a potential pleiotropic role of LPR2 in 
CVD development but also links of SZT2 to hyperten-
sion regulation.
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